losartan has been researched along with Albuminuria in 166 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 10.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in." | 9.27 | Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. ( Abbate, M; Belviso, A; Bossi, AC; Carrara, F; de Borst, M; Diadei, O; Gaspari, F; Iliev, IP; Parvanova, A; Peraro, F; Perna, A; Podestà, MA; Remuzzi, G; Rubis, N; Ruggenenti, P; Ruggiero, B; Stucchi, N; Trevisan, R; Trillini, M, 2018) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 9.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "In this post-hoc analysis of a randomized crossover study, 33 T2DM subjects with albuminuria received either 50 mg of losartan or 20 mg of quinapril (both 50% maximal dose) daily for 4 weeks with 4-week wash-out period in between." | 9.19 | Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. ( Lim, SC; Liu, JJ; Subramaniam, T; Sum, CF, 2014) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 9.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 9.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 9.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| " Losartan significantly reduced albuminuria relative to placebo and carvedilol (27." | 9.12 | Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. ( Biedunkiewicz, B; Chamienia, A; Rutkowski, B; Tylicki, L; Wojnarowski, K; Zdrojewski, Z, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 9.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 9.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria." | 9.10 | Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. ( Baggen, MG; Bootsma, AH; de Zeeuw, D; Lamberts, SW; Ouwendijk, RJ; Zandbergen, AA, 2003) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 9.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 9.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 9.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 9.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "A double-blind, randomized, 12 weeks study of the effects on enalapril 20 mg (n = 46) vs losartan 50 mg daily (n = 47) on blood pressure, albuminuria, fasting blood glucose, and lipids in 57 male and 36 female patients with essential hypertension." | 9.08 | Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. ( Dollerup, J; Jensen, HA; Mogensen, CE; Nielsen, B; Nielsen, S, 1997) |
| " We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation." | 7.85 | Aliskiren reduces albuminuria after kidney transplantation. ( Biedunkiewicz, B; Chamienia, AL; Debska-Slizien, AM; Heleniak, Z; Lizakowski, S; Małgorzewicz, S; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2017) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 7.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 7.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "The influence of losartan and the endothelin A and B receptor antagonist, bosentan was assessed on the alterations in renal hemodynamic and function as well as urinary albumin excretion (taken as an index of renal lesions) associated with L-NAME hypertension." | 7.70 | [Renal alterations in L-NAME hypertension: influence of losartan and bosentan]. ( Demeilliers, B; Herizi, A; Jover, B; Mimran, A, 1998) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 6.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Losartan treatment did not influence the increase in urinary excretion of sodium during infusion of atrial natriuretic factor, whereas enalapril treatment significantly attenuated this increase (P < 0." | 6.69 | Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. ( Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998) |
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 6.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "Losartan shows minimal adverse effects and no influence on graft function and biomarkers of graft fibrosis." | 5.51 | Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. ( Biedunkiewicz, B; Chamienia, A; Dębska-Ślizień, A; Głyda, M; Heleniak, Z; Konopa, J; Kuźmiuk-Glembin, I; Lizakowski, S; Pięta, R; Renke, M; Rutkowski, B; Tylicki, L, 2022) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 5.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Both enalapril and losartan treatment reduced the acute albuminuria, measured 1 day after injection of a monoclonal antibody against aminopeptidase A, by 91% and 83%, respectively." | 5.29 | Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? ( Assmann, KJ; de Jong, AS; Dijkman, HB; Koene, RA; Mentzel, S; van Son, JP; Wetzels, JF, 1996) |
| "In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in." | 5.27 | Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. ( Abbate, M; Belviso, A; Bossi, AC; Carrara, F; de Borst, M; Diadei, O; Gaspari, F; Iliev, IP; Parvanova, A; Peraro, F; Perna, A; Podestà, MA; Remuzzi, G; Rubis, N; Ruggenenti, P; Ruggiero, B; Stucchi, N; Trevisan, R; Trillini, M, 2018) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 5.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "In this post-hoc analysis of a randomized crossover study, 33 T2DM subjects with albuminuria received either 50 mg of losartan or 20 mg of quinapril (both 50% maximal dose) daily for 4 weeks with 4-week wash-out period in between." | 5.19 | Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. ( Lim, SC; Liu, JJ; Subramaniam, T; Sum, CF, 2014) |
| " The Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/hydrochlorothiazide (HCTZ) combination is superior to high-dose losartan in not only reducing morning systolic blood pressure (SBP) but also ameliorating urinary albumin excretion (UAE) after 3-month treatment." | 5.17 | Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. ( Adachi, H; Imaizumi, T; Kai, H; Kaneyuki, M; Kusaba, K; Mitsutake, Y; Shihara, M; Toyama, Y; Ueda, T; Umei, H, 2013) |
| "We conducted a quasi-experimental, validation study in which patients with primary, uncomplicated hypertension received open-label, fixed combination therapy with amlodipine/losartan 5/50 mg or 5/100 mg according to their baseline blood pressure (BP)." | 5.17 | Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). ( Pérez Carreño, JG; Romero, JD; Villar Centeno, JC, 2013) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 5.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years." | 5.14 | Renal and retinal effects of enalapril and losartan in type 1 diabetes. ( Donnelly, S; Drummond, K; Gardiner, R; Goodyer, P; Gubler, MC; Klein, R; Mauer, M; Sinaiko, A; Strand, T; Suissa, S; Zinman, B, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 5.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| " We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily)." | 5.14 | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. ( Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL, 2009) |
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 5.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| "Aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy." | 5.14 | Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010) |
| " We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy." | 5.13 | Aliskiren combined with losartan in type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| " Losartan significantly reduced albuminuria relative to placebo and carvedilol (27." | 5.12 | Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. ( Biedunkiewicz, B; Chamienia, A; Rutkowski, B; Tylicki, L; Wojnarowski, K; Zdrojewski, Z, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| " We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy." | 5.12 | Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. ( Andersen, S; Lajer, M; Parving, HH; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 5.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 5.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "Forty-one ARB- and ACE inhibitor-naive T2DM subjects with albuminuria (>30 mg/g creatinine) were given either 50 mg of losartan (ARB) or 20 mg of quinapril (ACE inhibitor) (50% maximum dose) for 4 weeks, with a 4-week wash-out period in-between interventions in a crossover fashion." | 5.12 | Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. ( Chua, CL; Goh, SK; Heng, BL; Koh, AF; Lim, SC; Subramaniam, T; Sum, CF, 2007) |
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "Absence of BP response to losartan does not preclude a reduction in albuminuria, and optimal reduction of albuminuria may require titration beyond the predefined BP target." | 5.11 | Renoprotection with and without blood pressure reduction. ( Andersen, S; de Zeeuw, D; Laverman, GD; Navis, G; Parving, HH; Rossing, P, 2005) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria." | 5.10 | Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. ( Baggen, MG; Bootsma, AH; de Zeeuw, D; Lamberts, SW; Ouwendijk, RJ; Zandbergen, AA, 2003) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 5.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "Twenty-one subjects with hypertension and AER between 10 and 200 microg/min were randomized to receive either 50 mg losartan daily (n = 11) or placebo (n = 10)." | 5.10 | Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. ( Akdeniz, A; Cooper, ME; Gilbert, RE; Houlihan, CA; Jerums, G; Tsalamandris, C, 2002) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "We investigated whether a relationship exists between circulating transforming growth factor beta -1 (TGF-beta(1)), collagen type I metabolism, microalbuminuria, and left ventricular hypertrophy in essential hypertension and whether the ability of the angiotensin II type 1 receptor antagonist losartan to correct microalbuminuria and regress left ventricular hypertrophy in hypertensives is related to changes in TGF-beta(1) and collagen type I metabolism." | 5.09 | Transforming growth factor beta in hypertensives with cardiorenal damage. ( Díez, J; Laviades, C; Varo, N, 2000) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 5.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 5.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We compared the efficacy of treatment protocols with an angiotensin converting enzyme (ACE) inhibitor alone (enalapril, 5 mg) or angiotensin II (ATII) receptor blocker (losartan, 50 mg) or both enalapril plus losartan in patients with microalbuminuria in a prospective, randomized clinical trial." | 5.09 | Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. ( Gedik, O; Gürlek, A; Tütüncü, NB, 2001) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 5.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "A double-blind, randomized, 12 weeks study of the effects on enalapril 20 mg (n = 46) vs losartan 50 mg daily (n = 47) on blood pressure, albuminuria, fasting blood glucose, and lipids in 57 male and 36 female patients with essential hypertension." | 5.08 | Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. ( Dollerup, J; Jensen, HA; Mogensen, CE; Nielsen, B; Nielsen, S, 1997) |
| "Effects of losartan and amlodipine on blood pressure and albuminuria were compared in a randomized, double-blind, parallel trial involving 48 patients with essential hypertension (sitting diastolic blood pressure between 95 to 115 mm Hg) and impaired renal function (creatinine clearance of 30 to 60 ml/min/1." | 5.08 | Comparison of losartan and amlodipine in renally impaired hypertensive patients. ( Aranda, P; Casado, S; Fernández-Andrade, C; Guerra, L; Iversen, B; Russo, D; Zucchelli, P, 1998) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| " We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation." | 3.85 | Aliskiren reduces albuminuria after kidney transplantation. ( Biedunkiewicz, B; Chamienia, AL; Debska-Slizien, AM; Heleniak, Z; Lizakowski, S; Małgorzewicz, S; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2017) |
| "We have previously shown that an association of losartan and hydrochlorothiazide, initiated 1 mo after 5/6 nephrectomy (Nx), reversed hypertension and albuminuria and promoted lasting renoprotection." | 3.83 | An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. ( Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016) |
| "This study used data from three randomized intervention trials (Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy, Selective Vitamin D Receptor Activation for Albuminuria Lowering, and Residual Albuminuria Lowering with Endothelin Antagonist Atrasentan) including patients with type 2 diabetes and macroalbuminuria." | 3.81 | Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. ( Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F, 2015) |
| "The aim of this study was to evaluate the effect of compound 21 (C21), a selective AT2 receptor agonist, on diabetic nephropathy and the potential additive effect of C21, when associated with losartan treatment, on the development of albuminuria and renal fibrosis in Zucker diabetic fatty (ZDF) rats." | 3.80 | Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. ( Bombardi, C; Carletti, R; Castoldi, G; Dahlöf, B; di Gioia, CR; Maestroni, S; Steckelings, UM; Stella, A; Unger, T; Zerbini, G, 2014) |
| " The aim of this study is to evaluate the direct effects of losartan and/or pentoxifylline on expression of renal DDAH-1 and its relation to oxidative stress in the setting of albuminuria." | 3.79 | Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy. ( Ahn, JS; Cho, JH; Choi, JY; Hyun, SH; Kim, CD; Kim, YL; Oh, EJ; Oh, SH; Park, SH; Ryu, HM; Yoon, SH, 2013) |
| "Adult patients with angiotensin receptor blocker (ARB)-resistant essential hypertension (n = 104) were enrolled and switched to combination therapy with losartan (50 mg/day) and hydrochlorothiazide (12." | 3.79 | Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension. ( Asakura, J; Hasegawa, H; Iwashita, T; Kawashima, K; Matsuda, A; Mitarai, T; Nakamura, T; Ogawa, T; Shimizu, T; Takayanagi, K; Tayama, Y, 2013) |
| "Aliskiren significantly attenuated albuminuria and glomerular mesangial matrix expansion in db/db mice, which was associated with the improvement of the increased glomerular transforming growth factor-beta and type IV collagen expressions, the increased macrophage infiltration, and the decreased glomerular nephrin expression of db/db mice." | 3.76 | Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E, 2010) |
| "In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.76 | Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010) |
| "After 12 weeks of the treatment with losartan, albuminuria was reduced from baseline by 9% [95% confidence interval (CI): 1-17, p = 0." | 3.76 | Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. ( Ajdinović, B; Andelković, Z; Dragović, T; Hrvacević, R; Ilić, V; Kocev, N; Magić, Z, 2010) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 3.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 3.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "Despite discontinuation of losartan over the subsequent six months, ARB pre-treatment completely prevented proteinuria and hypertension in these slow renal ablation rats." | 3.74 | Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats. ( Jeong, HJ; Kim, KH; Kim, Y; Mauer, M; Park, HW; Rozen, S; Shin, MH, 2007) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| "We examined the effects of combined treatment with SMP-534 and losartan on urinary albumin and glomerular fibrosis in db/db mice." | 3.73 | Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006) |
| "In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.73 | Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006) |
| "The influence of losartan and the endothelin A and B receptor antagonist, bosentan was assessed on the alterations in renal hemodynamic and function as well as urinary albumin excretion (taken as an index of renal lesions) associated with L-NAME hypertension." | 3.70 | [Renal alterations in L-NAME hypertension: influence of losartan and bosentan]. ( Demeilliers, B; Herizi, A; Jover, B; Mimran, A, 1998) |
| "Losartan and captopril have comparable effects on reducing albuminuria in a diabetic rat model." | 3.70 | The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. ( Ahiskali, R; Akalin, S; Budak, Y; Ekicioglu, G; Emerk, K; Ersöz, O; Kuçükkaya, B; Yavuz, DG, 1999) |
| "Participants were American Indians with type 2 diabetes enrolled in a clinical trial of losartan versus placebo." | 2.90 | Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. ( Boustany-Kari, CM; Esplin, CA; Guarnieri, P; Harder, JL; Hill, J; Kretzler, M; Looker, HC; Mauer, M; Nair, V; Najafian, B; Nelson, RG; Saulnier, PJ, 2019) |
| "In patients with type 2 diabetes, by comparison, the mean percentage of podocyte detachment was significantly higher in macroalbuminuria (1." | 2.77 | Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. ( Blouch, K; Jones, LI; Lemley, KV; Lovato, T; Mason, CC; Myers, BD; Nelson, RG; Richardson, M; Weil, EJ; Yee, B, 2012) |
| " The adverse effects included dry cough (seven [19." | 2.75 | Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. ( Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 2.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "Losartan has been shown to protect the diabetic kidney, at least partly independent of changes in blood pressure." | 2.72 | The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. ( Baggen, MG; Boersma, E; Bootsma, AH; Janssen, JA; Lamberts, SW; Zandbergen, AA, 2006) |
| "Using FAM to treat 31 patients with diabetic nephropathy and controlled by 23 patients treated with Losartan, the therapeutic course was 3 months for both groups, changes of clinical symptoms, blood glucose, lipid metabolism and urinary albumin were observed and compared." | 2.71 | [Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture]. ( Chen, YP; Wang, HY, 2004) |
| "Nine IDDM patients with microalbuminuria (30-300 mg/24 h) were studied." | 2.70 | Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. ( Buter, H; de Jong, PE; de Zeeuw, D; Dullaart, RP; Navis, G, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Losartan treatment did not influence the increase in urinary excretion of sodium during infusion of atrial natriuretic factor, whereas enalapril treatment significantly attenuated this increase (P < 0." | 2.69 | Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. ( Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998) |
| "Eight IgA nephropathy patients with documented clinical and histological indicators of poor prognosis were given 50 mg of losartan, 10 mg of enalapril, and 40 mg of the NO donor isosorbide 5 mononitrate (as a control of NO generation) in randomized order for 7 days each." | 2.69 | Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy. ( Bancale, E; Cacace, G; Cesano, G; Gigliola, G; Mengozzi, G; Mosso, R; Paradisi, L; Picciotto, G; Piccoli, G; Polloni, R; Roccatello, D; Rossi, D; Sena, LM, 2000) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "The major goal of treating high blood pressure in this population is to prevent or reduce the likelihood of target-organ damage." | 2.42 | Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? ( Lakkis, J; Lu, WX; Weir, MR, 2003) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "Albuminuria was defined as urine albumin/creatinine ratio ≥30 mg/g." | 1.91 | Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy. ( Ahmad, MI; Chen, LY; Kazibwe, R; Singh, S; Soliman, EZ; Soliman, MZ, 2023) |
| "Data from patients with type 2 diabetes and microalbuminuria (n = 49) treated with irbesartan 300 mg/day were used for discovery." | 1.43 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. ( Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P, 2016) |
| "Losartan-treated pups exhibited disturbances in renal function and structure that persisted into adulthood." | 1.40 | The role of oxidative stress in renal injury induced in rats by losartan exposure during lactation. ( Coimbra, TM; Costa, RS; da Silva, CG; Francescato, HD; Marin, EC, 2014) |
| " Doses were adjusted to equipotent inhibition of the renin-angiotensin system, determined via a dose-response quantifying plasma and renal renin expression." | 1.38 | AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. ( Baucke, J; Danser, AH; Divac, N; Fraune, C; Frenay, AR; Garrelds, IM; Hölzel, A; Jankowski, V; Krebs, C; Lange, S; Nguyen, G; Schwedhelm, E; Stahl, R; Streichert, T; van Goor, H; Velden, J; Wenzel, UO, 2012) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | 1.36 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "Diabetic nephropathy is the main cause of end-stage renal disease." | 1.34 | Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 1.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide." | 1.33 | Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. ( Brenner, BM; Chan, J; de Zeeuw, D; Kurokawa, K; Lash, JP; Ramjit, D; Remuzzi, G; Ribeiro, AB; Shahinfar, S; Zhang, Z, 2006) |
| "Losartan normalized blood pressure, cardiac hypertrophy, albuminuria, inflammatory response and morphological changes in mREN2 rats, both in the presence and absence of cyclooxygenase inhibitors." | 1.32 | Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). ( Cheng, ZJ; Finckenberg, P; Louhelainen, M; Merasto, S; Mervaala, EM; Tikkanen, I; Vapaatalo, H, 2003) |
| "Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1." | 1.31 | Optimal dose of losartan for renoprotection in diabetic nephropathy. ( Andersen, S; Deinum, J; Juhl, TR; Parving, HH; Rossing, P, 2002) |
| "Losartan can inhibit those deteriorations besides blood pressure lowering." | 1.31 | [Relationship of hypertensive microalbuminuria and endothelial and glomerular impairment]. ( Sun, M; Wu, J; Zhou, HY, 2002) |
| " With this background, this study was undertaken to evaluate how the chronic administration of deoxycortisone acetate (DOCA) modifies the effects of losartan on BP, renal injury, and other variables in L-NAME hypertensive rats." | 1.31 | Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats. ( DE Gracia, MC; Del Moral, RG; Del Rio, CG; O'Valle, F; Osuna, A; Vargas, F; Wangensteen, R, 2000) |
| "There is evidence that preeclampsia results from a breakdown in the balance between vasodilators such as prostacyclin and prostaglandin E2 and nitric oxide and the vasoconstrictors angiotensin II, thromboxane A2, serotonin, and endothelin." | 1.30 | The role of AT1 angiotensin receptor activation in the pathogenesis of preeclampsia. ( Doering, TP; Freeman, EJ; Haller, NA; Hopkins, MP; Montgomery, MA, 1998) |
| "Both losartan and enalapril treatments maintained conscious BP at comparably lowered levels compared to control animals (116 +/- 6 mm Hg and 113 +/- 2 mm Hg vs." | 1.29 | Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. ( Fitzgibbon, WR; Hutchison, FN; Imamura, A; Lacy, ER; Mackenzie, HS; Ploth, DW, 1995) |
| "Both enalapril and losartan treatment reduced the acute albuminuria, measured 1 day after injection of a monoclonal antibody against aminopeptidase A, by 91% and 83%, respectively." | 1.29 | Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? ( Assmann, KJ; de Jong, AS; Dijkman, HB; Koene, RA; Mentzel, S; van Son, JP; Wetzels, JF, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (10.24) | 18.2507 |
| 2000's | 87 (52.41) | 29.6817 |
| 2010's | 56 (33.73) | 24.3611 |
| 2020's | 6 (3.61) | 2.80 |
| Authors | Studies |
|---|---|
| Mårup, FH | 1 |
| Peters, CD | 1 |
| Christensen, JH | 1 |
| Birn, H | 1 |
| Kuźmiuk-Glembin, I | 1 |
| Heleniak, Z | 2 |
| Pięta, R | 1 |
| Głyda, M | 1 |
| Lizakowski, S | 2 |
| Renke, M | 2 |
| Konopa, J | 1 |
| Chamienia, A | 2 |
| Biedunkiewicz, B | 3 |
| Rutkowski, B | 3 |
| Tylicki, L | 3 |
| Dębska-Ślizień, A | 1 |
| Eita, MAH | 1 |
| Ashour, RH | 1 |
| El-Khawaga, OY | 1 |
| Yoo, TH | 1 |
| Hong, SJ | 1 |
| Kim, S | 1 |
| Shin, S | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 1 |
| Lee, S | 1 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 1 |
| Park, S | 1 |
| Ahmad, MI | 1 |
| Kazibwe, R | 1 |
| Soliman, MZ | 1 |
| Singh, S | 1 |
| Chen, LY | 1 |
| Soliman, EZ | 1 |
| Huang, WJ | 1 |
| Meng, X | 1 |
| Yang, F | 1 |
| Bao, Q | 1 |
| Zhang, MZ | 1 |
| Yang, YN | 1 |
| Ni, Q | 1 |
| Lian, FM | 1 |
| Tong, XL | 1 |
| Gao, D | 1 |
| Yu, P | 1 |
| Jing, S | 1 |
| Yan, C | 1 |
| Ding, D | 1 |
| Qiao, Y | 1 |
| Wu, G | 1 |
| Debska-Slizien, AM | 1 |
| Przybylska, M | 1 |
| Chamienia, AL | 1 |
| Rutkowski, P | 1 |
| Małgorzewicz, S | 1 |
| Quinn, CT | 1 |
| Saraf, SL | 1 |
| Gordeuk, VR | 1 |
| Fitzhugh, CD | 1 |
| Creary, SE | 1 |
| Bodas, P | 1 |
| George, A | 1 |
| Raj, AB | 1 |
| Nero, AC | 1 |
| Terrell, CE | 1 |
| McCord, L | 1 |
| Lane, A | 1 |
| Ackerman, HC | 1 |
| Yang, Y | 1 |
| Niss, O | 1 |
| Taylor, MD | 1 |
| Devarajan, P | 1 |
| Malik, P | 1 |
| Fujihara, CK | 6 |
| Kowala, MC | 1 |
| Breyer, MD | 1 |
| Sena, CR | 2 |
| Rodrigues, MV | 1 |
| Arias, SCA | 2 |
| Fanelli, C | 3 |
| Malheiros, DM | 5 |
| Jadhav, PK | 1 |
| Montrose-Rafizadeh, C | 1 |
| Krieger, JE | 1 |
| Zatz, R | 7 |
| Parvanova, A | 1 |
| Trillini, M | 1 |
| Podestà, MA | 1 |
| Iliev, IP | 1 |
| Ruggiero, B | 1 |
| Abbate, M | 1 |
| Perna, A | 1 |
| Peraro, F | 1 |
| Diadei, O | 1 |
| Rubis, N | 1 |
| Gaspari, F | 1 |
| Carrara, F | 1 |
| Stucchi, N | 1 |
| Belviso, A | 1 |
| Bossi, AC | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 7 |
| de Borst, M | 1 |
| Ruggenenti, P | 2 |
| Yun, L | 1 |
| Xu, X | 1 |
| Dai, Y | 1 |
| Xu, R | 1 |
| Li, G | 2 |
| Yao, Y | 1 |
| Li, J | 2 |
| Zheng, F | 1 |
| Ougaard, ME | 1 |
| Jensen, HE | 1 |
| Thuen, ID | 1 |
| Petersen, EG | 1 |
| Kvist, PH | 1 |
| Li, L | 1 |
| Guan, Y | 1 |
| Kobori, H | 1 |
| Morishita, A | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Nakano, D | 1 |
| Nishiyama, A | 1 |
| Ávila, VF | 1 |
| Foresto-Neto, O | 1 |
| Faustino, VD | 1 |
| Malheiros, DMAC | 1 |
| Camara, NOS | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Looker, HC | 1 |
| Mauer, M | 5 |
| Saulnier, PJ | 1 |
| Harder, JL | 1 |
| Nair, V | 1 |
| Boustany-Kari, CM | 1 |
| Guarnieri, P | 1 |
| Hill, J | 1 |
| Esplin, CA | 1 |
| Kretzler, M | 1 |
| Nelson, RG | 2 |
| Najafian, B | 3 |
| Arias, SC | 2 |
| Valente, CP | 1 |
| Machado, FG | 1 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Kai, H | 2 |
| Kaneyuki, M | 1 |
| Shihara, M | 1 |
| Toyama, Y | 1 |
| Mitsutake, Y | 1 |
| Umei, H | 1 |
| Kusaba, K | 1 |
| Ueda, T | 2 |
| Adachi, H | 1 |
| Imaizumi, T | 2 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 2 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Park, SH | 1 |
| Hyun, SH | 1 |
| Ryu, HM | 1 |
| Ahn, JS | 1 |
| Oh, SH | 1 |
| Oh, EJ | 1 |
| Yoon, SH | 1 |
| Choi, JY | 1 |
| Cho, JH | 1 |
| Kim, CD | 1 |
| Kim, YL | 1 |
| Nagata, T | 1 |
| Fukuzawa, T | 1 |
| Takeda, M | 1 |
| Fukazawa, M | 1 |
| Mori, T | 1 |
| Nihei, T | 1 |
| Honda, K | 1 |
| Suzuki, Y | 1 |
| Kawabe, Y | 1 |
| Liu, Y | 1 |
| Jia, Z | 1 |
| Liu, S | 1 |
| Downton, M | 1 |
| Liu, G | 1 |
| Du, Y | 1 |
| Yang, T | 1 |
| Issa, N | 1 |
| Ortiz, F | 1 |
| Reule, SA | 1 |
| Kukla, A | 1 |
| Kasiske, BL | 1 |
| Jackson, S | 2 |
| Matas, AJ | 1 |
| Ibrahim, HN | 2 |
| Pérez Carreño, JG | 1 |
| Romero, JD | 1 |
| Villar Centeno, JC | 1 |
| Hasegawa, H | 1 |
| Tayama, Y | 1 |
| Takayanagi, K | 1 |
| Asakura, J | 1 |
| Nakamura, T | 2 |
| Kawashima, K | 1 |
| Shimizu, T | 1 |
| Iwashita, T | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Mitarai, T | 1 |
| Rosendahl, A | 1 |
| Niemann, G | 1 |
| Lange, S | 2 |
| Ahadzadeh, E | 1 |
| Krebs, C | 2 |
| Contrepas, A | 1 |
| van Goor, H | 2 |
| Wiech, T | 1 |
| Bader, M | 1 |
| Schwake, M | 1 |
| Peters, J | 1 |
| Stahl, R | 2 |
| Nguyen, G | 2 |
| Wenzel, UO | 2 |
| Imbalzano, E | 1 |
| Scarpelli, M | 1 |
| Mandraffino, G | 1 |
| Creazzo, M | 1 |
| Lizio, G | 1 |
| Trapani, G | 1 |
| Dattilo, G | 1 |
| Dalbeni, A | 1 |
| Tomasello, C | 1 |
| Sardo, MA | 1 |
| Saitta, A | 1 |
| Volkova, NI | 1 |
| Lazoryshynets, VV | 1 |
| Castoldi, G | 1 |
| di Gioia, CR | 1 |
| Bombardi, C | 1 |
| Maestroni, S | 1 |
| Carletti, R | 1 |
| Steckelings, UM | 1 |
| Dahlöf, B | 10 |
| Unger, T | 1 |
| Zerbini, G | 1 |
| Stella, A | 1 |
| Kröpelin, TF | 1 |
| de Zeeuw, D | 14 |
| Andress, DL | 1 |
| Bijlsma, MJ | 1 |
| Persson, F | 4 |
| Parving, HH | 18 |
| Heerspink, HJ | 2 |
| Schievink, B | 1 |
| Rossing, P | 10 |
| Lambers Heerspink, HJ | 2 |
| Vishram, JK | 1 |
| Devereux, RB | 8 |
| Ibsen, H | 8 |
| Kjeldsen, SE | 7 |
| Lindholm, LH | 6 |
| Mancia, G | 1 |
| Okin, PM | 5 |
| Rothwell, PM | 1 |
| Wachtell, K | 9 |
| Olsen, MH | 9 |
| Souza, RA | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 2 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Zhu, Q | 1 |
| Qi, X | 1 |
| Wu, Y | 1 |
| Wang, K | 1 |
| Pena, MJ | 1 |
| Heinzel, A | 1 |
| Dallmann, G | 1 |
| Rossing, K | 1 |
| Andersen, S | 7 |
| Mayer, B | 1 |
| Palevsky, PM | 1 |
| Zhang, JH | 1 |
| Seliger, SL | 1 |
| Emanuele, N | 1 |
| Fried, LF | 1 |
| Lewis, JB | 4 |
| Lewis, EJ | 3 |
| Hollenberg, NK | 3 |
| Narita, T | 2 |
| Hosoba, M | 1 |
| Miura, T | 1 |
| Sasaki, H | 1 |
| Morii, T | 2 |
| Fujita, H | 2 |
| Kakei, M | 1 |
| Ito, S | 1 |
| Yuan, KL | 1 |
| Shi, XZ | 1 |
| Lu, X | 1 |
| Gao, P | 1 |
| Xu, GW | 1 |
| Ikeda, H | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Kohlmann, O | 1 |
| Roca-Cusachs, A | 1 |
| Laurent, S | 1 |
| Schmieder, RE | 1 |
| Wenzel, RR | 1 |
| Fogari, R | 1 |
| Agha, A | 2 |
| Amer, W | 1 |
| Anwar, E | 2 |
| Bashir, K | 2 |
| Marshall, SM | 1 |
| Zhang, Y | 2 |
| Deb, DK | 2 |
| Kong, J | 2 |
| Ning, G | 2 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Zhang, Z | 9 |
| Strugnell, S | 1 |
| Sabbagh, Y | 1 |
| Arbeeny, C | 1 |
| Li, YC | 2 |
| Zinman, B | 1 |
| Gardiner, R | 1 |
| Suissa, S | 1 |
| Sinaiko, A | 1 |
| Strand, T | 1 |
| Drummond, K | 1 |
| Donnelly, S | 1 |
| Goodyer, P | 1 |
| Gubler, MC | 1 |
| Klein, R | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Kinouchi, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Itoh, H | 1 |
| Mehdi, UF | 1 |
| Adams-Huet, B | 1 |
| Raskin, P | 1 |
| Vega, GL | 1 |
| Toto, RD | 1 |
| Sun, T | 1 |
| Wong, KE | 1 |
| Shi, H | 1 |
| Chang, A | 1 |
| Kosmadakis, G | 1 |
| Filiopoulos, V | 1 |
| Georgoulias, C | 1 |
| Tentolouris, N | 1 |
| Michail, S | 1 |
| Dilauro, M | 1 |
| Zimpelmann, J | 1 |
| Robertson, SJ | 1 |
| Genest, D | 1 |
| Burns, KD | 1 |
| Tan, F | 1 |
| Mukherjee, JJ | 1 |
| Lee, KO | 1 |
| Lim, P | 1 |
| Liew, CF | 1 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Lai, ZF | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Søraas, CL | 1 |
| Tønnessen, T | 1 |
| Wang, H | 1 |
| Deng, JL | 1 |
| Yue, J | 1 |
| Hou, YB | 1 |
| Dragović, T | 1 |
| Ajdinović, B | 1 |
| Hrvacević, R | 1 |
| Ilić, V | 1 |
| Magić, Z | 1 |
| Andelković, Z | 1 |
| Kocev, N | 1 |
| Vieira, JM | 1 |
| Ventura, BH | 1 |
| Vaňourková, Z | 1 |
| Kramer, HJ | 1 |
| Husková, Z | 1 |
| Cervenka, L | 1 |
| Vaněčková, I | 1 |
| Rahimi, Z | 1 |
| Felehgari, V | 1 |
| Rahimi, M | 1 |
| Mozafari, H | 1 |
| Yari, K | 1 |
| Vaisi-Raygani, A | 1 |
| Rezaei, M | 1 |
| Malek-Khosravi, S | 1 |
| Khazaie, H | 1 |
| Titan, SM | 1 |
| Graciolli, FG | 1 |
| dos Reis, LM | 1 |
| Barros, RT | 1 |
| Jorgetti, V | 1 |
| Moysés, RM | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 2 |
| Berl, T | 1 |
| Packham, D | 1 |
| Sakamoto, T | 1 |
| Komatsu, K | 1 |
| Fujishima, H | 1 |
| Takahashi, T | 1 |
| Yamada, Y | 1 |
| Garcia-Touza, M | 1 |
| Sowers, JR | 1 |
| Weil, EJ | 1 |
| Lemley, KV | 1 |
| Mason, CC | 1 |
| Yee, B | 1 |
| Jones, LI | 1 |
| Blouch, K | 1 |
| Lovato, T | 1 |
| Richardson, M | 1 |
| Myers, BD | 1 |
| Fraune, C | 1 |
| Hölzel, A | 1 |
| Baucke, J | 1 |
| Divac, N | 1 |
| Schwedhelm, E | 1 |
| Streichert, T | 1 |
| Velden, J | 1 |
| Garrelds, IM | 1 |
| Danser, AH | 1 |
| Frenay, AR | 1 |
| Jankowski, V | 1 |
| Townsend, RR | 1 |
| Weir, MR | 3 |
| Connaire, J | 1 |
| Matas, A | 1 |
| Ney, A | 1 |
| West, A | 1 |
| Lentsch, N | 1 |
| Ericksen, J | 1 |
| Bodner, J | 1 |
| Kasiske, B | 1 |
| Lim, SC | 2 |
| Liu, JJ | 1 |
| Subramaniam, T | 2 |
| Sum, CF | 2 |
| Marin, EC | 1 |
| Francescato, HD | 1 |
| Costa, RS | 1 |
| da Silva, CG | 1 |
| Coimbra, TM | 1 |
| Juhl, TR | 3 |
| Deinum, J | 2 |
| Borch-Johnsen, K | 5 |
| Zanella, MT | 1 |
| Ribeiro, AB | 2 |
| Eguchi, K | 1 |
| Kario, K | 2 |
| Shimada, K | 2 |
| Jacobsen, P | 1 |
| Tarnow, L | 4 |
| Cheng, ZJ | 1 |
| Finckenberg, P | 1 |
| Louhelainen, M | 1 |
| Merasto, S | 1 |
| Tikkanen, I | 1 |
| Vapaatalo, H | 1 |
| Mervaala, EM | 1 |
| Wu, J | 1 |
| Sun, M | 1 |
| Zhou, HY | 1 |
| Cambien, F | 1 |
| Lu, WX | 1 |
| Lakkis, J | 1 |
| Qin, J | 1 |
| Liu, J | 1 |
| Sun, L | 1 |
| Hu, L | 1 |
| Cooper, ME | 7 |
| Cao, Z | 1 |
| Zandbergen, AA | 2 |
| Baggen, MG | 2 |
| Lamberts, SW | 2 |
| Bootsma, AH | 2 |
| Ouwendijk, RJ | 1 |
| Kubba, S | 1 |
| Agarwal, SK | 1 |
| Prakash, A | 1 |
| Puri, V | 1 |
| Babbar, R | 1 |
| Anuradha, S | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 2 |
| Ruilope, LM | 3 |
| Segura, J | 1 |
| Mandal, AK | 1 |
| Keane, WF | 5 |
| Shahinfar, S | 7 |
| Snapinn, S | 2 |
| Mitch, WE | 2 |
| Brenner, BM | 5 |
| Awad, AS | 1 |
| Webb, RL | 1 |
| Carey, RM | 1 |
| Siragy, HM | 1 |
| Satoh, S | 1 |
| Horikawa, Y | 1 |
| Kakinuma, H | 1 |
| Tsuchiya, N | 1 |
| Wang, L | 1 |
| Kato, T | 1 |
| Habuchi, T | 1 |
| Wang, HY | 1 |
| Chen, YP | 1 |
| Mogensen, CE | 4 |
| de Faire, U | 2 |
| Fyhrquist, F | 2 |
| Julius, S | 3 |
| Lederballe-Pedersen, O | 2 |
| Nieminen, MS | 4 |
| Omvik, P | 2 |
| Oparil, S | 2 |
| Wan, Y | 3 |
| Alexander, CM | 1 |
| Lyle, PA | 3 |
| Carides, GW | 1 |
| Schjoedt, KJ | 2 |
| Joshi, SR | 1 |
| Yeolekar, ME | 1 |
| Tripathi, KK | 1 |
| Giri, J | 1 |
| Maity, AK | 1 |
| Chopda, M | 1 |
| Gujarathi, S | 1 |
| Maroli, S | 1 |
| Maity, A | 1 |
| Navis, G | 2 |
| Velho, M | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Luño, J | 1 |
| Bella, JN | 1 |
| Palmieri, V | 1 |
| Gerdts, E | 1 |
| Smith, G | 1 |
| Wojnarowski, K | 1 |
| Zdrojewski, Z | 1 |
| Janssen, JA | 1 |
| Boersma, E | 1 |
| Snapinn, SM | 1 |
| Sugaru, E | 2 |
| Nakagawa, T | 2 |
| Ono-Kishino, M | 2 |
| Nagamine, J | 2 |
| Tokunaga, T | 2 |
| Kitoh, M | 2 |
| Hume, WE | 2 |
| Nagata, R | 2 |
| Taiji, M | 2 |
| Oikarinen, L | 2 |
| Ramjit, D | 1 |
| Kurokawa, K | 1 |
| Lash, JP | 1 |
| Chan, J | 1 |
| Lajer, M | 1 |
| Otani, L | 1 |
| Yasumatsu, T | 1 |
| Murakami, M | 1 |
| Hayashi, A | 1 |
| Kimoto, K | 1 |
| Murakami, T | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 1 |
| Struijker Boudier, HA | 1 |
| Woo, V | 1 |
| Ni, LS | 1 |
| Hak, D | 1 |
| Berard, L | 1 |
| Zhu, F | 1 |
| Khan, S | 1 |
| Ma, GM | 1 |
| Penner, B | 1 |
| Shen, GX | 1 |
| Eijkelkamp, WB | 1 |
| Gleim, GW | 1 |
| Koh, AF | 1 |
| Goh, SK | 1 |
| Chua, CL | 1 |
| Heng, BL | 1 |
| Park, HW | 1 |
| Kim, Y | 1 |
| Kim, KH | 1 |
| Jeong, HJ | 1 |
| Shin, MH | 1 |
| Rozen, S | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Yokoyama, H | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Tanaka, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Liu, F | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Chénier, I | 1 |
| Sachetelli, S | 1 |
| Zhang, SL | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Chan, JS | 1 |
| Tershakovec, AM | 1 |
| Appel, GB | 1 |
| McGill, JB | 1 |
| Viitasalo, M | 1 |
| Toivonen, L | 1 |
| Raz, I | 1 |
| Rugale, C | 1 |
| Cordaillat, M | 1 |
| Mimran, A | 2 |
| Jover, B | 2 |
| Piecha, G | 1 |
| Koleganova, N | 1 |
| Gross, ML | 1 |
| Geldyyev, A | 1 |
| Adamczak, M | 1 |
| Bakris, G | 1 |
| Burgess, E | 1 |
| Weir, M | 1 |
| Davidai, G | 1 |
| Koval, S | 1 |
| Imamura, A | 1 |
| Mackenzie, HS | 1 |
| Lacy, ER | 1 |
| Hutchison, FN | 2 |
| Fitzgibbon, WR | 1 |
| Ploth, DW | 1 |
| Baboolal, K | 1 |
| Meyer, TW | 1 |
| Gansevoort, RT | 1 |
| Redfield, A | 1 |
| de Jong, PE | 3 |
| Fauvel, JP | 1 |
| Velon, S | 1 |
| Berra, N | 1 |
| Pozet, N | 1 |
| Madonna, O | 1 |
| Zech, P | 1 |
| Laville, M | 1 |
| Mentzel, S | 1 |
| Assmann, KJ | 1 |
| Dijkman, HB | 1 |
| de Jong, AS | 1 |
| van Son, JP | 1 |
| Wetzels, JF | 2 |
| Koene, RA | 1 |
| Chan, JC | 1 |
| Critchley, JA | 1 |
| Tomlinson, B | 1 |
| Chan, TY | 1 |
| Cockram, CS | 1 |
| Nielsen, S | 1 |
| Dollerup, J | 1 |
| Nielsen, B | 1 |
| Jensen, HA | 1 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Shikada, K | 1 |
| Tanaka, S | 1 |
| Wagner, J | 1 |
| Drab, M | 1 |
| Bohlender, J | 1 |
| Amann, K | 1 |
| Wienen, W | 1 |
| Ganten, D | 1 |
| Vervoort, G | 1 |
| Hertenberg, F | 1 |
| Smits, P | 1 |
| Kaysen, GA | 1 |
| Webster, S | 1 |
| Al-Bander, H | 1 |
| Jones, H | 1 |
| Doering, TP | 1 |
| Haller, NA | 1 |
| Montgomery, MA | 1 |
| Freeman, EJ | 1 |
| Hopkins, MP | 1 |
| Demeilliers, B | 1 |
| Herizi, A | 1 |
| Fernández-Andrade, C | 1 |
| Russo, D | 1 |
| Iversen, B | 1 |
| Zucchelli, P | 1 |
| Aranda, P | 1 |
| Guerra, L | 1 |
| Casado, S | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Yavuz, DG | 1 |
| Ersöz, O | 1 |
| Kuçükkaya, B | 1 |
| Budak, Y | 1 |
| Ahiskali, R | 1 |
| Ekicioglu, G | 1 |
| Emerk, K | 1 |
| Akalin, S | 1 |
| Roccatello, D | 1 |
| Mengozzi, G | 1 |
| Gigliola, G | 1 |
| Rossi, D | 1 |
| Mosso, R | 1 |
| Cacace, G | 1 |
| Polloni, R | 1 |
| Cesano, G | 1 |
| Picciotto, G | 1 |
| Paradisi, L | 1 |
| Bancale, E | 1 |
| Piccoli, G | 1 |
| Sena, LM | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Buter, H | 2 |
| van Tol, A | 1 |
| Navis, GJ | 1 |
| Scheek, LM | 1 |
| Dullaart, RP | 2 |
| Laviades, C | 1 |
| Varo, N | 1 |
| Díez, J | 1 |
| DE Gracia, MC | 1 |
| Osuna, A | 1 |
| O'Valle, F | 1 |
| Del Moral, RG | 1 |
| Wangensteen, R | 1 |
| Del Rio, CG | 1 |
| Vargas, F | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| Esmatjes, E | 1 |
| Flores, L | 1 |
| Iñigo, P | 1 |
| Lario, S | 1 |
| Campistol, JM | 1 |
| Bloomgarden, ZT | 1 |
| Açbay, O | 1 |
| Tütüncü, NB | 1 |
| Gürlek, A | 1 |
| Gedik, O | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Houlihan, CA | 2 |
| Allen, TJ | 1 |
| Baxter, AL | 1 |
| Panangiotopoulos, S | 1 |
| Casley, DJ | 1 |
| Jerums, G | 2 |
| Ersoy, A | 1 |
| Dilek, K | 1 |
| Usta, M | 1 |
| Yavuz, M | 1 |
| Güllülü, M | 1 |
| Oktay, B | 1 |
| Yurtkuran, M | 1 |
| Akdeniz, A | 1 |
| Tsalamandris, C | 1 |
| Gilbert, RE | 1 |
| Studney, D | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Tan, K | 1 |
| Chow, WS | 1 |
| Wong, Y | 1 |
| Shiu, S | 1 |
| Tam, S | 1 |
| Hutchinson, FN | 1 |
| Webster, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage[NCT03009864] | Early Phase 1 | 632 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| A Phase II Trial of Losartan to Reverse Sickle Nephropathy[NCT01479439] | Phase 2 | 36 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor T[NCT01393808] | Phase 2 | 112 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990] | Phase 4 | 153 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955] | Phase 2 | 496 participants | Interventional | 2004-10-31 | Completed | ||
| Renin Angiotensin System Blockage-DN (RASS)[NCT00143949] | Phase 2 | 285 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus[NCT00419835] | Phase 4 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation[NCT05285878] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-07-28 | Enrolling by invitation | ||
| No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449] | Phase 1 | 36 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [NCT03019848] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt N[NCT00168857] | Phase 4 | 860 participants (Actual) | Interventional | 2003-07-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of participants who have a ≥25% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to 6 months. This is a categorical outcome (yes/no).~We hypothesized and pre-specified that ≥30% of the subjects in the microalbuminuria group would meet this outcome." (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan - No Albuminuria | 1 |
| Losartan - Microalbuminuria | 7 |
| Losartan - Macroalbuminuria | 5 |
Fold-change in creatinine clearance by 24h urine collection (GFR-CrCl) from baseline (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Fold-change (Median) |
|---|---|
| No Albuminuria (NoA) | 0.06 |
| Microalbuminuria (MicroA) | 0.12 |
| Macroalbuminuria | 0.05 |
Fold-change in UACR from baseline (NCT01479439)
Timeframe: Baseline and 6 months
| Intervention | Fold-change (Median) |
|---|---|
| No Albuminuria (NoA) | 0.08 |
| Microalbuminuria (MicroA) | -0.46 |
| Macroalbuminuria | -0.74 |
Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 6 |
| Placebo | 12 |
Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 7 |
| Placebo | 15 |
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
11 reviews available for losartan and Albuminuria
| Article | Year |
|---|---|
Prostaglandin E1 for preventing the progression of diabetic kidney disease.
Topics: Albuminuria; Alprostadil; Diabetic Nephropathies; Disease Progression; Drugs, Chinese Herbal; Fosino | 2010 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2005 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
77 trials available for losartan and Albuminuria
| Article | Year |
|---|---|
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum | 2022 |
Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients.
Topics: Albuminuria; Allografts; Biomarkers; Cardiovascular Diseases; Fibrosis; Heart Disease Risk Factors; | 2022 |
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Case-Control Studies; China; Diabetic Nephropathi | 2019 |
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Anemia, Sickle Cell; Child; Female; Glomerular Filtrati | 2017 |
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Topics: Aged; Albuminuria; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Double-Bl | 2018 |
Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.
Topics: Adult; Albuminuria; Analysis of Variance; Biopsy, Needle; Diabetes Mellitus, Type 2; Diabetic Nephro | 2019 |
Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2013 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.
Topics: Adult; Albuminuria; Aldosterone; Allografts; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Bi | 2014 |
Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study).
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2013 |
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
Topics: Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diastole; Drug The | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Crea | 2016 |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Amides; Angiotensin II Type 1 Receptor Bloc | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus | 2009 |
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S | 2009 |
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2010 |
FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabe | 2011 |
Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antioxidant | 2011 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2012 |
Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biopsy; Capillaries; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Angiotensin II blockade in kidney transplant recipients.
Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe | 2013 |
Angiotensin II blockade in kidney transplant recipients.
Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe | 2013 |
Angiotensin II blockade in kidney transplant recipients.
Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe | 2013 |
Angiotensin II blockade in kidney transplant recipients.
Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe | 2013 |
Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2014 |
Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2 | 2003 |
Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics.
Topics: Adult; Albuminuria; Antihypertensive Agents; Autonomic Nervous System Diseases; Diabetes Mellitus, T | 2003 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
[Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture].
Topics: Adult; Albuminuria; Astragalus propinquus; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli | 2004 |
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetic Angiopathies; Drug Combi | 2004 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2005 |
Renoprotection with and without blood pressure reduction.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, Renal; Lo | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients.
Topics: Albuminuria; Blood Pressure; Carbazoles; Carvedilol; Cyclosporine; Female; Humans; Kidney Function T | 2006 |
The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Diabetes Mellitus, | 2006 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cytochrome P-450 CYP11B | 2006 |
Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Coagulation Factors; Blood | 2006 |
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Aged; Albuminuria; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2007 |
Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angio | 2007 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressur | 2008 |
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Gl | 1994 |
Effects of losartan on renal function in patients with essential hypertension.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Com | 1996 |
Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Ca | 1997 |
Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atri | 1998 |
Comparison of losartan and amlodipine in renally impaired hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium; Creatine; Fe | 1998 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Femal | 2000 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Cholesterol; Cholesterol, LDL; Cholesterol, VL | 2000 |
Transforming growth factor beta in hypertensives with cardiorenal damage.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Collagen; Collagen Type I; Female; Humans; Hyp | 2000 |
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 2001 |
Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
A low-sodium diet potentiates the effects of losartan in type 2 diabetes.
Topics: Albuminuria; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cr | 2002 |
Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients.
Topics: Adolescent; Adult; Albuminuria; Angiotensin II; Antihypertensive Agents; Blood Pressure; Female; Hum | 2002 |
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria.
Topics: Albuminuria; Antihypertensive Agents; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephro | 2002 |
79 other studies available for losartan and Albuminuria
| Article | Year |
|---|---|
Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy: Role of combined losartan.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2022 |
Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Electrocardiography; Heart Failure; Hum | 2023 |
miR-193a as a potential mediator of WT-1/synaptopodin in the renoprotective effect of Losartan on diabetic kidney.
Topics: Adult; Aged; Albuminuria; Animals; Diabetic Retinopathy; Female; Gene Expression; Humans; Losartan; | 2022 |
Aliskiren reduces albuminuria after kidney transplantation.
Topics: Adult; Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Double-Blind Method; Female; Fumarates | 2017 |
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor | 2017 |
The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Collagen; Drug Therapy, Combination; Female; Hyperten | 2018 |
Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Di | 2018 |
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Age | 2019 |
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Female; G | 2019 |
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
Topics: Acetylglucosaminidase; Albuminuria; Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animal | 2013 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blo | 2013 |
Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diab | 2013 |
Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relatio | 2013 |
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H | 2014 |
[Microalbuminuria as a marker of endothelial dysfunction in the long-term follow-up patients after surgical correction of aortic coarctation].
Topics: Adolescent; Adult; Albuminuria; Antihypertensive Agents; Aorta, Thoracic; Aortic Coarctation; Biomar | 2013 |
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Topics: Albuminuria; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug | 2014 |
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasen | 2015 |
An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
Topics: Albuminuria; Animals; Blood Pressure; Drug Combinations; Furosemide; Hydrochlorothiazide; Hypertensi | 2016 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2016 |
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Drug Therapy, Combination; Female; Glomerula | 2016 |
Low dose of losartan decreased urinary excretions of IgG, transferrin, and ceruloplasmin without reducing albuminuria in normoalbuminuric type 2 diabetic patients.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Ceruloplasmin; Diabetes Mellit | 2008 |
[Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Biomarkers; Chromatography, Gas; Creatinine; Deoxyguanosin | 2007 |
Intensive diabetes management for high-risk patients: how best to deliver?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca | 2009 |
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cyto | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Crea | 2010 |
Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 2010 |
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, | 2010 |
Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure | 2010 |
Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Press | 2010 |
Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
Topics: Albuminuria; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 2011 |
AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressur | 2012 |
Angiotensin II blockade after kidney transplantation.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Female; Humans; Kidney Transplantation; Losart | 2013 |
The role of oxidative stress in renal injury induced in rats by losartan exposure during lactation.
Topics: Albuminuria; Animals; Apoptosis; Biomarkers; Blood Pressure; Body Weight; Creatinine; Drinking Behav | 2014 |
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Diabetic Nephropathies; | 2002 |
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Follow-Up Studies; H | 2002 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Topics: Albuminuria; Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood | 2003 |
[Relationship of hypertensive microalbuminuria and endothelial and glomerular impairment].
Topics: Albuminuria; Animals; Antihypertensive Agents; Endothelium, Vascular; Glomerular Mesangium; Hyperten | 2002 |
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diabetes | 2003 |
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea N | 2003 |
Summaries for patients. The blood pressure drug losartan appears to benefit the kidneys of people with type 2 diabetes who do not have high blood pressure.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Losartan for microalbuminuria in normotensive type 2 diabetes mellitus.
Topics: Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Losartan | 2004 |
Losartan for microalbuminuria in normotensive type 2 diabetes mellitus.
Topics: Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Losartan; Monitoring, Physiologic | 2004 |
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood | 2004 |
Clinical characteristics of normotensive renal transplant recipients with microalbuminuria and effects of angiotensin II type I receptor antagonist on urinary albumin excretion.
Topics: Acetylglucosaminidase; Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; | 2004 |
An extremely high dose of losartan affords superior renoprotection in the remnant model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Anima | 2005 |
Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Diabetic Nephropathies; D | 2006 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr | 2006 |
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2006 |
Reduction of salt sensitivity in stroke-prone spontaneously hypertensive rats administered an AT1 receptor antagonist during suckling.
Topics: Albuminuria; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; An | 2006 |
[Kidney protection leads to heart protection, too].
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2006 |
Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
Topics: Albuminuria; Animals; Antihypertensive Agents; Benzamides; Diabetic Nephropathies; Disease Models, A | 2007 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diabe | 2007 |
Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Administration S | 2007 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Topics: Albuminuria; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Fai | 2008 |
Albuminuria: a great risk marker, but an underestimated target in diabetes.
Topics: Albuminuria; Antihypertensive Agents; Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Humans; | 2008 |
Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate.
Topics: Albuminuria; Animals; Blood Pressure; Canrenoic Acid; Dose-Response Relationship, Drug; Glomerular F | 2008 |
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type IV; Desmin; Dihydralazi | 2008 |
Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats.
Topics: Albuminuria; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphen | 1995 |
The effect of acute angiotensin II blockade on renal function in rats with reduced renal mass.
Topics: Albuminuria; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Hypertension, Renal; Imida | 1994 |
Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect?
Topics: Acute Disease; Albuminuria; Aminopeptidases; Angiotensin II; Angiotensin-Converting Enzyme Inhibitor | 1996 |
Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 1997 |
Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 1998 |
High-protein diets augment albuminuria in rats with Heymann nephritis by angiotensin II-dependent and -independent mechanisms.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 1998 |
The role of AT1 angiotensin receptor activation in the pathogenesis of preeclampsia.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Endotoxins; Female; Fetus; L | 1998 |
[Renal alterations in L-NAME hypertension: influence of losartan and bosentan].
Topics: Albuminuria; Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Enzyme Inh | 1998 |
The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Anions; Antihypertensive Agents; Captopril; | 1999 |
Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats.
Topics: Albuminuria; Animals; Blood Pressure; Blood Proteins; Creatinine; Desoxycorticosterone; Enzyme Inhib | 2000 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Enalapri | 1992 |